Shanxi Teamgene Biological announced that it will receive funding by Shandong Teamgene Technology Co., Ltd. on December 9, 2022. The proposal on the use of part of the raised proceeds to carry out a capital increase in wholly-owned subsidiaries to be used for the implementation of investment projects has been approved by the first special shareholders? meeting for 2022 .
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
11.54 CNY | +1.05% | -1.20% | -23.53% |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-23.53% | 267M | |
+4.77% | 10.73B | |
-1.93% | 5.68B | |
+16.84% | 5.14B | |
+1.00% | 5.09B | |
-35.40% | 2.18B | |
-1.08% | 1.83B | |
-28.53% | 1.05B | |
+42.84% | 980M | |
-23.60% | 809M |
- Stock Market
- Equities
- 603151 Stock
- News Shandong Teamgene Technology Co., Ltd.
- Shanxi Teamgene Biological announced that it expects to receive funding from Shandong Teamgene Technology Co., Ltd.